The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has directed Zydus ...

Discover a study that suggests that dual therapy could offer a safer and more effective approach to treating MASLD.

Strong chronic therapy performance, BSV consolidation drive revenue growth in Q4; net profit declines 10 per cent ...

Heart failure is responsible not only for high morbidity and mortality, but also for significant out-of-pocket expenses for ...

If the new data is added to the label of Jardiance (empagliflozin), the SGLT2 inhibitor would become the first in the class to be approved to treat all types of chronic heart failure as well as ...

Top of the agendas was chronic kidney disease (CKD), an area where Boehringer is already making an impact with blockbuster SGLT2 inhibitor Jardiance (empagliflozin). Jardiance was originally ...

Shares of Mankind Pharma dropped over 3 per cent after it posted a 10 per cent fall in consolidated net profit Q4 FY25 ...

The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to ...

A recent study published in the journal GeroScience has discovered that a diabetes drug called Empagliflozin (Empa) might ...

Cardiovascular disease remains the leading cause of death in patients with diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to ...